Restriction of hepatitis C virus heterogeneity during prolonged interferon-α therapy in relation to changes in virus load

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 992-996

  Yun, Z B ^b   Odeberg, J ^b   Lundeberg, J ^b   Weiland, O ^b   Uhlen M ^b   Sonnerborg A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ARTICLE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0029888656     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.992     Document Type: Article

References (15)

1. Martel M, Astiban J, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-9.
2. Higashi Y, Kakumu S, Yoshioka K, et al. Dynamics of genome change in the E2/N1 region of hepatitis C virus in vivo. Virology 1993;197:659-68.
3. Weiner AJ, Geysen HM, Christophron C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992;89:3468-72.
4. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to Interferon therapy in viremic patients. Hepatology 1992;16:619-24.
5. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994;75:1361-9.
6. Kumar U, Brown J, Monjard OJ, Thomas HC. Sequence variation in large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis 1993;167:726-30.
7. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
8. Odeberg J, Yun ZB, Sönnerborg A, Uhlén M, Lundeberg J. Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. J Clin Microbiol 1995;33:1870-4.
9. Yun ZB, Lindh G, Weiland O, Johansson B, Sönnerborg A. Hepatitis C virus (HCV) RNA related to HCV antibody pattern in serum and liver histology in Swedish blood donors. J Med Virol 1993;1:37-42.
10. Reichard O, Foberg U, Frydén A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C following treatment with interferon alpha-2b for 60 weeks. Hepatology 1994;19:280-5.
11. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-90.
12. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451-5.
13. Yun ZB, Lundeberg J, Johansson B, et al. Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. J Virol Methods 1994;47:1-14.
14. Schvarcz R, Yun ZB, Sönnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-7.
15. Mizokami M, Lau JYN, Suzuki K, Nakano T, Gojobori T. Differential sensitivity of hepatitis C virus quasispecies to interferon-α therapy. J Hepatol 1994;21:884-6.